RESEARCH USE ONLY. Reference data for laboratory research. Not medical advice; not for human consumption.
Peptijournal
Calc

Compare compounds

Pick up to 3 compounds to see protocols, mechanisms, study endpoints and safety findings side by side.

PopularRetatrutide vs TirzepatideSemaglutide vs TirzepatideSemaglutide vs RetatrutideBPC-157 vs TB-500BPC-157 vs GHK-CuSermorelin vs Tesamorelin
ARA-290
Same goal
Include when printing

Only affects the printed page / PDF. The research-use-only notice always prints.

Protocol01
ARA-290

Tissue Repair

Vials · 10 mg

01Protocol

Vials
10 mg
Dosing data
Lab reference — not listed

02Quick calculator

Draw (100u)

—

Concentration

—

mg/mL

03Mechanism of action

ARA-290 (cibinetide) is an 11-amino-acid peptide derived from erythropoietin that activates the innate repair receptor without stimulating red-blood-cell production. It is studied for small-nerve-fibre damage and neuropathic pain.

04Study endpoints

  • Sarcoidosis small-fibre neuropathy RCT: corneal nerve fibre area rose significantly at day 28 in one arm, skin nerve fibres increased, and pain improved in all groups.
  • Type 2 diabetes neuropathy RCT: neuropathic symptoms (PainDetect) improved and HbA1c and lipid profiles improved over 56 days.

05Safety & regulatory findings

  • Not approved by the FDA or EMA for any indication; research-grade material is not a medicine.
  • No potential safety issues were identified in the type 2 diabetes trial; trials were small and short.

06Citations

2 references · view